forecast glp-1 prescriptions growth 2025 semaglutide tirzepatide Monitoring Report: RA Prescribing Trends – September Data Impact of the CVS GLP-1

Several observational studies have reported greater 12-month weight loss with tirzepatide than semaglutide approved for the treatment of type 2 diabetes, but differences in follow-up duration, dosing, and adherence limit comparability with shorter-term outcomes [12, 13]

Pancreatitis Warning: Patients should discontinue use if pancreatitis is suspected

Additionally, NHS prescribing criteria require participation in lifestyle intervention as part of the treatment protocol

It has been shown previously that 14% weight loss due to a very-low-energy diet (VLED) resulted in counter-regulatory changes in appetite-regulating hormones, including a significant increase in fasting levels of ghrelin and significant reductions in the fasting levels of leptin, GLP-1, peptide YY (PYY), cholecystokinin (CCK) and amylin 48

Improved metabolic health: Beyond its primary effects on blood sugar and weight, Semaglutide contributes to overall metabolic health

Not yet for weight loss federal law currently prohibits Part D from covering weight loss medications